Disease Focused

These include focused libraries of small-molecule compounds with potential biological activity towards certain diseases (such as Anti-Cancer Compound Library, Anti-Diabetic Compound Library, Anti-Cardiovascular Disease Compound Library, etc.).

Cat No.	product name
L1800	Anti-Infection Compound Library	A unique collection of 2977 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc;	2977 compounds
L2620	Anti-Neurodegenerative Disease Compound Library	A unique collection of 1622 compounds related to neurodegenerative diseases can be used for HTS or HCS；	1622 compounds
L2191	Anti-Breast Cancer Compound Library	A unique collection of 1436 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study；	1436 compounds
L9840	Anti-Alzheimer's Disease Compound Library	A unique collection of 1040 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS.	1040 compounds
L2170	Immuno-Oncology Compound Library	A unique collection of 454 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；	454 compounds
L4710	Nonsteroidal Anti-Inflammatory Compound Library	530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.	530 compounds
L4700	Immunology/Inflammation Compound Library	A unique collection of 3483 anti-inflammation compounds effective for high throughput screening and high content screening.	3483 compounds
L1719	Nsp15-Targeted Compound Library (CADD)	A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	470 compounds
L4510	Anti-Parasitic Compound Library	525 well-chosen unique anti-parasitic small molecules;	525 compounds
L2180	Anti-Cancer Library Plus	Well-chosen 1468 anti-tumor compounds with unique structures;	1468 compounds
L1900	Anti-Diabetic Compound Library	A unique collection of 690 diabetes related compounds;	690 compounds
L1715	Nsp16-Targeted Compound Library (CADD)	A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	281 compounds
L2152	Targeted Therapy Drug Library	121 tumor-targeted drugs that can be used for high-throughput and high-content screening.	121 compounds
L2192	Anti-Pancreatic Cancer Compound Library	A unique collection of 1697 pancreatic cancer related compounds can be used in HTS and HCS;	1697 compounds
L4660	Anti-Nervous System Disease Library	Well-chosen 1246 compounds with unique structures targeting nervous system;	1246 compounds
L1716	PLpro-Targeted Compound Library (CADD)	A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	474 compounds
L4520	Anti-Bacterial Compound Library	A unique collection of 1429 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;	1429 compounds
L9810	Anti-Fibrosis Compound Library	A unique collection of 1180 potential anti-fibrosis compounds, can be used in HTS and HCS;	1180 compounds
L1714	RBD-Targeted Compound Library (CADD)	A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	206 compounds
L5400	Anti-Cardiovascular Disease Compound Library	A unique collection of 1428 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	1428 compounds
L2120	Anti-Cancer Clinical Compound Library	A unique collection of 1990 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);	1990 compounds
L1710	Anti-COVID-19 Compound Library	A unique collection of 2446 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；	2446 compounds
L2160	Anti-Cancer Active Compound Library	A unique collection of 2114 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	2114 compounds
L2151	Chemotherapy Drug Library	51 Chemotherapeutic drugs that can be used for high-throughput and high-content screening.	51 compounds
L9830	Anti-Parkinson's Disease Compound Library	A unique collection of 908 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS.	908 compounds
L8400	Hematonosis Compound Library	A unique collection of 524 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);	524 compounds
L2140	Cancer Cell Differentiation Compound Library	A unique collection of 413 cancer cell differentiation inducing compounds for high throughput and high content screening;	413 compounds
L7110	Anti-Hypertension Compound Library	719 hypertension-related small molecules for high-throughput and high-content screening.	719 compounds
L2100	Anti-Cancer Compound Library	A unique collection of 5885 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	5885 compounds
L2150	Anti-Cancer Drug Library	A unique collection of 2478 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);	2478 compounds
L1700	Anti-Virus Compound Library	A unique collection of 800 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;	800 compounds
L1717	RdRP-Targeted Compound Library (CADD)	A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	464 compounds
L4500	Anti-Fungal Compound Library	A unique collection of 253 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.	253 compounds
L2110	Anti-Cancer Approved Drug Library	A unique collection of 1726 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);	1726 compounds
L7100	Anti-Obesity Compound Library	A unique collection of 1359 anti-obesity compounds for high throughput and high content screening;	1359 compounds
L1711	Anti-COVID-19 Compound Library (CADD)	A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	362 compounds
L2190	Anti-Lung Cancer Compound Library	A unique collection of 1566 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；	1566 compounds
L1718	X Domain-Targeted Compound Library (CADD)	A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	463 compounds
L1712	3CLpro-Targeted Compound Library (CADD)	A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	161 compounds
L5200	Anti-Metabolism Disease Compound Library	A unique collection of 1558 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	1558 compounds
L2130	Anti-Cancer Metabolism Compound Library	A unique collection of 1280 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);	1280 compounds
L1713	ACE2-Targeted Compound Library (CADD)	A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	462 compounds